NIDA Clinical Trials Network: Big South/West Node

NIDA 临床试验网络：大南/西节点

• 批准号: 10176433
• 负责人: Jennifer Sharpe Potter
• 金额: $ 1057.57万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-01 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10176433
• 关键词: AIDS prevention; Academy; Address; African American; American; American Indians; Ancillary Study; Area; Arkansas; Buprenorphine; Bupropion; California; Caring; Cause of Death; Clinical; Clinical Treatment; Clinical Trials Network; Collaborations; Communities; Databases; Development; Disease; Dissemination and Implementation; Doctor of Philosophy; Dose; Drug abuse; Drug usage; Electronic Health Record; Ethnic group; Evidence based practice; Family Physicians; Foundations; Funding; Geographic Locations; Geography; Goals; HIV; HIV Seropositivity; HIV/HCV; Health; Health Sciences; Healthcare Systems; Hepatitis C virus; Hispanics; Immigrant; Informatics; Infrastructure; International; Lead; Leadership; Length of Stay; Los Angeles; Louisiana; Measurement; Medical center; Mentors; Methamphetamine; Mission; Modeling; Multi-Institutional Clinical Trial; NCI Scholars Program; Naltrexone; Names; National Institute of Drug Abuse; Native Americans; Oklahoma; Opioid; Patient Discharge; Peer Review; Persons; Pharmacotherapy; Population; Prevention; Primary Health Care; Productivity; Public Health; Publications; Publishing; Race; Recovery; Research; Research Design; Research Personnel; Resources; Risk; Rural; Science; Scientist; Senior Scientist; Site; Solid; Substance Use Disorder; Testing; Texas; Training; Transcranial magnetic stimulation; Translational Research; Underinsured; Universities; Workforce Development; addiction; base; clinical care; cohort; comorbidity; design; experience; health care settings; hospital readmission; implementation science; implementation study; improved; indexing; innovation; medically underserved population; methamphetamine use; metropolitan; multi-site trial; next generation; novel; opioid epidemic; opioid use disorder; patient population; programs; racial diversity; readmission risk; response; risk prediction; rural area; rural setting; screening; stimulant use; stimulant use disorder; substance misuse; substance use; therapy development; underserved area; urban setting

ABSTRACT The Big South/West Node of the NIDA Clinical Trials Network (CTN) represents an expansion of the Texas Node that has been a part of the CTN since 2005. With this expansion, the node will now be guided by the shared leadership of Madhukar H. Trivedi, MD of University of Texas Southwestern Medical Center (UTSW) Steven Shoptaw, PhD of UCLA, and Jennifer S. Potter, PhD, MPH, of UT Health Science Center at San Antonio (UTHSCSA). This fourth competing renewal application builds on our successful track record of leading CTN trials, being good network partners by providing excellent sites for multi-site studies, high productivity in publishing, and training the next generation of scientists. During the 2015-2020 funding cycle, our team developed and led: the largest pharmacotherapy trial for the treatment of methamphetamine use disorder to date (extended-release naltrexone plus high-dose bupropion; CTN0068 ADAPT-2), an in-depth study of the causes of death in a cohort of people living with HIV/HCV and substance use disorder (CTN0064A1), and an implementation study to develop and deploy universal screening for opioid use disorder and measurement based care using buprenorphine (CTN0090 MBC4OUD). Finally, a study testing transcranial magnetic stimulation (TMS) as a treatment for stimulant use disorder has been approved for development, in collaboration with the Southern Consortium Node (CTN0108). For this renewal application, we capitalize on the experience of the Multiple PIs, who collectively have expertise in the treatment of stimulants, the treatment of and public health response to the opioid crisis, and the treatment and care of HIV. Additional investigators bring content expertise spanning addiction science and clinical care, translational science, dissemination and implementation science, informatics, and trial implementation. The expanded Big South/West Node is named to denote the importance of including geographic regions in the South that have historically not been represented within the CTN (i.e., Arkansas, Oklahoma, Louisiana). This geographical expansion provides greater access to diverse patient populations (e.g., diverse racial and ethnic groups; underinsured; underserved; native [American Indian] and immigrant groups) within diverse settings (e.g., rural, urban). Our existing partnerships with primary care networks, large health care systems, and use of electronic health records (EHR) to positively impact substance use, has been further broadened to include multiple statewide networks and resources in new partner states. Our research agenda includes a focus on the fourth wave of the opioid epidemic, building upon the expertise of our investigators in treating stimulant and opioid use disorders, and the changing needs of the regions we serve. Our team has experience with innovative study designs that target all areas of the translational science continuum, and equip our Node to successfully and significantly improve the care of persons who misuse substances.

抽象的 NIDA临床试验网络（CTN）的大南/西节点代表得克萨斯州的扩展 自2005年以来一直是CTN的一部分的节点。随着此扩展，该节点现在将由该节点进行指导 德克萨斯大学西南医学中心（UTSW）的Madhukar H. Trivedi的共同领导 加州大学洛杉矶分校的史蒂芬·史速塔（Steven Shoptaw）博士和SAN UT健康科学中心的Jennifer S. Potter博士 安东尼奥（UTHSCSA）。第四次竞争的续订应用程序以我们成功的记录为基础 领先的CTN试验，通过为多站点研究提供出色的网站，成为良好的网络合作伙伴 出版和培训下一代科学家的生产力。在2015 - 2020年的资金周期中， 我们的团队开发和领导：用于治疗甲基苯丙胺的最大药物治疗试验 到目前为止的障碍（扩展释放纳曲酮加高剂量安非他酮； CTN0068 Adapt-2），深度 研究艾滋病毒/HCV和药物使用障碍的人群中死亡原因的研究 （CTN0064A1）和一项实施研究，以开发和部署阿片类药物使用障碍的普遍筛查 使用丁丙诺啡（CTN0090 MBC4OUD）和基于测量的护理。最后，一项研究测试经颅 磁刺激（TMS）作为刺激使用障碍的治疗 与南部财团节点（CTN0108）的合作。对于此续签应用，我们利用 多个PI的经验，他们在兴奋剂的治疗中统称具有专业知识，治疗 以及对阿片类药物危机以及艾滋病毒的治疗和护理的公共卫生反应。其他调查人员 带来跨越成瘾科学和临床护理，转化科学，传播和的内容专业知识 实施科学，信息学和试验实施。扩展的大南/西节点是命名的 表示在历史上不存在的南部地理区域的重要性 代表CTN（即阿肯色州，俄克拉荷马州，路易斯安那州）。这种地理扩展提供了 更多地进入多种患者人群（例如，不同的种族和种族群体；投资不足； 服务不足；在各种环境（例如，农村，城市）内（例如，美国印第安人]和移民群体）。我们的 与初级保健网络，大型医疗保健系统以及电子健康的使用现有合作伙伴关系 记录（EHR）以积极影响物质使用，已进一步扩大，包括多个全州 新合作伙伴国家的网络和资源。我们的研究议程包括关注第四波 阿片类药物流行，基于我们研究人员在治疗刺激和阿片类药物使用障碍方面的专业知识， 以及我们服务的地区的需求不断变化。我们的团队具有创新研究设计的经验 针对转化科学连续体的所有领域，并使我们的节点成功地，显着地 改善滥用物质的人的护理。